BIOCORP Announces Partnership with AARDEX Group to Extend Smart Solutions for Precision Medication Adherence
1.10.2020 08:30:00 EEST | Business Wire | Press release
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / Eligible PEA PME), a French company specialized in the design, development and manufacture of innovative medical devices, today announced an alliance with Belgium-based AARDEX Group, the world leader in medication adherence solutions.
This alliance is to combine BIOCORP’s connected add-on solutions for drug delivery devices with AARDEX’s proprietary Medication Event Monitoring System (MEMS®) and offer a comprehensive solution to patients and healthcare providers to effectively measure and manage medication adherence. The financial terms of the agreement have not been disclosed, however the first initiative will be to integrate BIOCORP’s Injay connected solution for Pre-filled syringes (PFS) to AARDEX’s MEMS Adherence Software (MEMS AS®), to target medicines delivered by PFS with potential applications in the field of Rheumatoid Arthritis, Multiple Sclerosis, Ophthalmology, Psoriasis or Cardiovascular diseases. The roadmap also includes integration with BIOCORP’s other connected devices, to cover further chronic conditions in the field of injectable, respiratory, and beyond.
David Dalla Vecchia, CEO and Financial Lead of AARDEX Group, said: "We are delighted to announce our partnership with BIOCORP. Our vision is to continuously innovate in data-driven medication adherence solutions to enhance digital therapeutics and patient empowerment. Partnering with BIOCORP - a true pioneer in connected devices - will significantly contribute to that objective and bring together a wealth of knowledge and experience to help meet the needs of today’s clinical trials, patients and healthcare providers.”
Éric Dessertenne, CEO of BIOCORP, concluded: “This collaboration with AARDEX Group brings a strong added value to our products and to our targeted users. Thanks to the integration with MEMS AS, a unique solution that analyzes deeply patient patterns and behaviors, we will go beyond just monitoring treatment adherence, by providing comprehensive and tailored solutions to boost patient’s engagement and effectively manage this issue. AARDEX specific expertise in clinical trials is also a strong asset and will enable us to create relationships with pharma companies right from the development stage of a drug”.
Medication adherence issues are well known by all healthcare stakeholders and its clinical and commercial impact have been quantified and heavily documented for many years now. The World Health Organization has stated that, in developed countries, adherence to long-term therapies in the general population is only around 50%. But this issue is not limited to commercialized drugs and real-life conditions, it also massively affects clinical trials, which impacts assessment of drug efficacy.
ABOUT AARDEX GROUP
AARDEX Group is the world leader in digital solutions to measure and manage medication adherence. Located in Belgium, in Switzerland and in the U.S., AARDEX develops and markets digital solutions for adherence-enhancing strategies in clinical trials, research settings, and professional healthcare systems. AARDEX is the central actor of a complete ecosystem that combines its MEMS® Adherence Software with a wide range of smart packages and devices that measure patient adherence across all routes of drug administration. Our vision is to continuously innovate in data-driven medication adherence solutions to enhance digital therapeutics and patient empowerment.
For more information, visit www.aardexgroup.com
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This intelligent sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of diabetics. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 54 employees.
BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200930005883/en/
Contact information
FOR MEDIA ENQUIRIES - ON BEHALF OF AARDEX GROUP
Sophie Beattie
sophie@discovery-pr.com
Mobile: + 44 (0) 7494 129 339
BIOCORP CONTACTS
Jacques Gardette
Chairman of the Board
investisseurs@biocorp.fr
Éric Dessertenne
Chief Executive Officer
Sylvaine Dessard
Marketing & Communication Director
rp@biocorp.fr
+ 33 (0)6 88 69 72 85
ULYSSE COMMUNICATION CONTACTS
Bruno ARABIAN
barabian@ulysse-communication.com
+33 (0)6 87 88 46 26
Nicolas DANIELS
ndaniels@ulysse-communication.com
+33 (0)6 63 66 59 22
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ExaGrid Wins 4 Industry Awards at the Storage Awards25.6.2026 15:00:00 EEST | Press release
ExaGrid®, the world’s largest independent backup storage vendor providing Tiered Backup Storage with the most Comprehensive Security and AI-Powered Retention Time-Lock for Ransomware Recovery, today announced that the company was honored with four industry awards during the 23rd annual Storage Awards ceremony, “The Storries,” held in London on June 18, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260625584191/en/ The ExaGrid team headed to the stage four times throughout the Storage Awards ceremony in London to accept awards for ExaGrid Tiered Backup Storage. Photo courtesy of Storage Awards. ExaGrid was named Data Protection Company of the Year, Immutable Storage Company of the Year, Storage Company of the Year, andjointly received the Storage Solution of the Year - Corporate award with key channel partner Convergent Technology. ExaGrid continues to gain recognition for its Tiered Backup Storage, winning 11 industry
2026 Esri User Conference to Focus on Creating a More Intelligent World with GIS25.6.2026 15:00:00 EEST | Press release
Esri, the global leader in geographic information system (GIS) technology, today announced speakers and the conference theme for the 2026 Esri User Conference. The conference will be held from July 13 to 17 at the San Diego Convention Center in San Diego, California. This year's theme of "GIS—Creating a more intelligent world" will emphasize how GIS turns the science of "where" into shared understanding and coordinated action—at the scale of communities, enterprises, and the planet. Kristine Tompkins, president and cofounder of Tompkins Conservation, will join Esri president Jack Dangermond as a keynote speaker for this year's Plenary Session. Tompkins is the former CEO of Patagonia and has worked to create parklands, conserve marine spaces, and promote biodiversity over the past three decades. Tompkins and Dangermond will also be joined by special guests from the City of Allentown (Pennsylvania), NextEra Energy, Rete Ferroviaria Italiana, National Weather Service, National Geographic
Copeland Releases FY2025 Global Impact Report Highlighting Energy Efficiency, Safety and Innovation Progress25.6.2026 15:00:00 EEST | Press release
Copeland, a global leader in compression technologies and controls solutions, has released its second annual Global Impact Report. The report highlights the company’s Fiscal Year 2025 (FY25) progress across environmental sustainability, workplace safety and community impact, guided by its Purpose, Performance and People pillars. Copeland has advanced its sustainability commitments through three strategic areas of focus: Performance-Driven Decarbonization: Copeland reduced Scope 1 and Scope 2 greenhouse gas emissions by 20% year-over-year, advancing toward its Science Based Targets initiative (SBTi)-validated goal of a 55% absolute reduction by FY33, using FY23 as a baseline.2 Renewable energy procurement and onsite solar generation accounted for 58% of total global electricity use. Aligned Innovation: Copeland dedicated more than 4% of annual revenue to engineering, research and new product development in FY25. The company also accelerated average product testing and engineering cycles
SUTEL Deploys Tecnotree Platform to Modernize Mobile Prepaid Registration and Strengthen Digital Security and Trust in Costa Rica25.6.2026 14:26:00 EEST | Press release
The Superintendence of Telecommunications (SUTEL) is advancing the modernization of Costa Rica’s Mobile Prepaid Registration System through the implementation of a new technological platform provided by Tecnotree designed to strengthen user identification processes, enhance regulatory compliance, and improve the overall customer experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260625307287/en/ This initiative is part of SUTEL’s ongoing efforts to promote digital transformation within the telecommunications sector while reinforcing security, transparency, and trust in digital communications across the country. The new Tecnotree platform incorporates advanced identity verification mechanisms, biometric authentication capabilities, and fraud prevention tools that will enable a more efficient and secure registration process for prepaid mobile subscribers. By improving the reliability of subscriber information, the solu
MRM Health Strengthens Board with Michel Detheux as Chairman and Hans-Jürgen Wörle as Independent Director as MH002 Advances Through Phase 2b25.6.2026 14:00:00 EEST | Press release
MRM Health, a clinical-stage biotech developing microbiome-based therapies for immune-mediated diseases, today announced the appointment of two experienced industry leaders to its Board of Directors as the Company enters a pivotal phase of growth. With its lead program, MH002, in Phase 2b clinical development, recent FDA Fast Track designation and a €55 million Series B financing, MRM Health is strengthening its Board to support the Company through its next clinical, strategic and financing milestones. Michel Detheux, PhD, has been appointed Chairman of the Board of Directors, taking over from Werner Cautreels. Prof. Dr. med. Hans-Jürgen Wörle joins the Board as an Independent Director. “MRM Health is entering a pivotal phase, with MH002 advancing into Phase 2b clinical development and significant momentum across the business. The appointments of Michel and Hans-Jürgen significantly strengthen our Board with proven leaders in drug development, regulatory strategy, capital markets, stra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom